2022
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican Society
2021
Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years
Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. JAMA Internal Medicine 2021, 181: 1665-1668. PMID: 34459853, PMCID: PMC8406208, DOI: 10.1001/jamainternmed.2021.4832.Peer-Reviewed Original ResearchComparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old
Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening Among Women 40-64 Years Old. Journal Of The National Cancer Institute 2021, 113: 1515-1522. PMID: 33822120, PMCID: PMC8757313, DOI: 10.1093/jnci/djab063.Peer-Reviewed Original ResearchConceptsHigher cancer detection rateCancer detection rateBreast cancer screeningCancer screeningScreening outcomesBreast cancer screening outcomesDigital breast tomosynthesisCancer screening outcomesPopulation-level adoptionReal-world cohortMultivariable logistic regressionHigher biopsy ratesPatient-level analysisPopulation health impactDetection rateIncident cancerClinical outcomesWomen 40Biopsy rateObservational studyComparative effectivenessLogistic regressionYoung womenPrivate health insurersWomenUnderstanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding Regional Variation in the Cost of Breast Cancer Screening Among Privately Insured Women in the United States. Medical Care 2021, 59: 437-443. PMID: 33560712, PMCID: PMC8611614, DOI: 10.1097/mlr.0000000000001506.Peer-Reviewed Original Research
2020
Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Kunst N, Alarid-Escudero F, Aas E, Coupé VMH, Schrag D, Kuntz KM. Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2710-2718. PMID: 32998946, PMCID: PMC7747688, DOI: 10.1158/1055-9965.epi-20-0490.Peer-Reviewed Original ResearchConceptsCancer recurrence rateRecurrence rateRelative survival dataColorectal cancerSurvival dataColorectal cancer-related deathsDisease-specific survival dataStage II rectal cancerStage III colorectal cancerCancer-specific death ratesStage II colon cancerPopulation-based cancer registriesColorectal cancer interventionDiagnostic time periodsMetastatic recurrence ratesRate 6 monthsNonmetastatic colorectal cancerColorectal cancer recurrenceMonths of diagnosisAnnual recurrence rateEnd Results ProgramCancer-related deathColorectal cancer diagnosisDecision analytic modelMetastatic diseaseCost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsUse and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance
Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and Costs of Breast Cancer Screening for Women in Their 40s in a US Population With Private Insurance. JAMA Internal Medicine 2020, 180: 799-801. PMID: 32202606, PMCID: PMC7147248, DOI: 10.1001/jamainternmed.2020.0262.Peer-Reviewed Original Research